Agios Pharmaceuticals, Inc. research snapshot
AGIO AI stock analysis currently reads Agios Pharmaceuticals as a rare-disease biotech with one approved product PYRUKYND (mitapivat) and a key FDA catalyst for sickle cell disease by November 1, 2026. At the July 13, 2026 cutoff, the quoted price was $40.66, market capitalization was about $2.42 billion, and the main decision point was whether mitapivat approval in sickle cell disease can expand the addressable market enough to justify the current valuation. This is informational research and not investment advice.
Current price
$40.66
Market cap
$2.42 billion
AI score
55 / 100
Rating
Pipeline-driven biotech awaiting key FDA decision
Trend status
Catalyst-driven uptrend ahead of PDUFA date
Data cutoff (updated weekly)
July 13, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Agios sells PYRUKYND (mitapivat), a PK activator for rare hemolytic anemias including PK deficiency and thalassemia, with an sNDA under FDA priority review for sickle cell disease. | Medium |
| Moat | Regulatory exclusivity for PYRUKYND, IP protection around PK activation, specialized rare disease commercial infrastructure, and first-in-class positioning in PK deficiency and thalassemia. | Medium |
| Management | CEO Brian Goff (ex-Alexion) brings rare disease commercial expertise. Capital allocation has been disciplined: oncology divestiture to Servier in 2020 refocused the pipeline. Key-person risk is moderate. | Medium |
| Financial trend | Revenue is growing from product launch ($54M in FY2025), but the company remains pre-profit with a net loss of $413M in 2025. Cash position of $737M provides runway into 2027-2028. | Medium |
| Valuation | At ~37x TTM revenue and a cash-adjusted enterprise value around $1.7B, the market is pricing in SCD approval and meaningful commercial uptake. Safety margin is thin if the FDA decision is unfavorable. | Medium-low |
| Technical trend | Catalyst-driven uptrend ahead of PDUFA date. Stock has rallied from $22 to $46 over the past year. Use live moving averages, support, resistance, and volume confirmation before acting. | Medium |
| Risk level | The thesis can fail if the FDA rejects or delays mitapivat for SCD, if SCD commercial adoption disappoints, if cash burn requires dilutive financing, if competitors launch superior SCD therapies, or if pipeline candidates fail. | Medium-high |
| AI confidence | Medium data confidence for qualitative mapping and verified financials. Lower confidence for forward binary outcomes that depend on a single FDA decision. | Medium data confidence |
| Investment certainty | Low to medium certainty because biotech catalyst outcomes are inherently binary and the page provides a framework, not personalized buy or sell instructions. | Low to medium |
AGIO AI stock forecast
The AGIO AI stock forecast uses scenario ranges around the $40.66 quote rather than a point target. The near-term trajectory depends primarily on the FDA PDUFA date of November 1, 2026 for mitapivat in sickle cell disease. The bullish case requires SCD approval and strong launch traction; the base case assumes approval but measured uptake; the bearish case assumes a negative FDA decision or significant commercial headwinds.
$60.00 to $80.00
More likely if Agios receives FDA approval for mitapivat in SCD by the November 1 PDUFA date, payer coverage is favorable, and early launch metrics show strong prescriber adoption. Additional pipeline progress in ITP or PKU would add upside.
$35.00 to $55.00
More likely if FDA approves mitapivat for SCD but with labeling restrictions, or if approval comes through but SCD commercial adoption is gradual. PYRUKYND thalassemia and PK deficiency revenue continues growing steadily.
$18.00 to $30.00
More likely if the FDA issues a Complete Response Letter for SCD, if safety concerns emerge from ongoing trials, if cash burn forces dilutive equity financing, or if competing SCD therapies gain market share faster than expected.
AGIO AI technical analysis
AGIO AI technical analysis starts from the $40.66 quote. The stock has rallied sharply from its 52-week low of $22.24 on positive clinical and regulatory momentum. Because this static page does not fetch request-time chart data, moving averages and live momentum should be confirmed in a charting tool before use.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $40.66 | Current quote used for this page as of the July 13, 2026 data cutoff. |
| Near support | $35.00 to $37.00 | Estimated from recent pullback levels and the 50-day moving average zone. Treat as a planning zone, not a guaranteed floor. |
| Near resistance | $44.00 to $46.00 | The 52-week high near $46.00 is a clear resistance level. A close above this zone on above-average volume would signal momentum continuation. |
| 50-day moving average | Requires live chart confirmation | Use current chart data before acting. The page does not fetch request-time market data. |
| 200-day moving average | Requires live chart confirmation | Long-term trend confirmation should be checked against a live chart or broker data. |
| Momentum | Catalyst-driven uptrend | The stock has strong positive momentum from the Priority Review announcement and RISE UP Phase 3 data. Momentum could shift quickly after the FDA decision. |
| Volume | Elevated near catalyst events | Volume has spiked on news days. Sustained above-average volume near resistance increases the chance of a breakout or reversal. |
| Volatility | Very high monitoring priority | Biotech binary event risk means wide daily swings are normal. Position sizing must account for potential 15-25% moves on FDA news. |
| Invalidation | Close below $35.00 | A decisive close below the support zone would weaken the short-term setup and suggest momentum has shifted. |
AGIO AI trading strategy
The AGIO AI trading strategy is a rules-based research framework. It is not personalized advice and should be paired with position sizing, stop levels, and fresh filings or news checks, especially around the November 1 PDUFA date.
Wait for AGIO to hold above near support and push through the $46.00 resistance zone with above-average volume that confirms buyer demand.
A close below the support zone or a failed breakout at resistance should invalidate the setup. Reduce position before the FDA decision to manage binary event risk.
If AGIO pulls back into the $35.00-$37.00 support band without a fundamental thesis break, compare price action with the next earnings, pipeline updates, and FDA timeline.
Do not average down without a predefined maximum loss and a fresh assessment of the risk-reward around the PDUFA date.
Track the evidence that matters most: FDA Advisory Committee meeting date and briefing documents, PDUFA decision on November 1, 2026, SCD launch metrics, and cash runway updates.
Reduce confidence when price moves are driven by speculation without new fundamental evidence. Consider defining position size based on the maximum loss you can tolerate from a negative FDA decision.
Investment research summary
Agios develops and commercializes PYRUKYND (mitapivat), a PK activator for rare hemolytic anemias including PK deficiency, thalassemia, and potentially sickle cell disease. The company sold its oncology business to Servier in 2020 to focus entirely on rare hematologic diseases.
Regulatory and IP protection for PK activation, first-in-class positioning in PK deficiency and thalassemia, specialized rare disease commercial and medical affairs infrastructure. The moat could widen if SCD approval is granted and the label is competitive.
The thesis can fail if the FDA does not approve mitapivat for SCD, if post-marketing safety issues emerge, if SCD launch fails to gain traction, if competitors develop superior oral therapies, if the pipeline disappoints, or if cash burn forces dilutive financing below current prices.
CEO Brian Goff (from Alexion, a successful rare disease commercial story) brings relevant experience. The decision to sell the oncology business and refocus on rare diseases was strategically sound. Management shows discipline in pipeline decisions as seen in the recent tebapivat LR-MDS discontinuation.
Rare disease genetics is a secular growth area in biopharma. SCD affects approximately 100,000 people in the US alone with significant unmet need. Gene therapies have entered the SCD space but face access and durability questions, leaving room for oral small molecule therapies like mitapivat.
At ~$2.42B market cap with $737M cash and minimal debt, the enterprise value is ~$1.7B. Current PYRUKYND revenue (~$54M annualized) does not support this valuation; the market is pricing in SCD approval and significant penetration. Margin of safety is low if the FDA decision is negative.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| AGIO price | $40.66 | Current quote snapshot cross-checked with Yahoo Finance and Barchart | July 13, 2026 |
| Market capitalization | $2.42 billion, verified as $40.66 x 59.47M shares using financial_rigor.py | financial_rigor.py market cap verification | July 13, 2026 |
| Shares outstanding | 59.47 million | Barchart and Yahoo Finance | July 13, 2026 |
| Cash position (mrq) | $737 million | Yahoo Finance balance sheet summary | July 13, 2026 |
| Revenue FY2025 | $54 million (cross-validated: Wikipedia $54.0M, Barchart $54.03M) | Wikipedia 10-K data and Barchart | July 13, 2026 |
| Net income FY2025 | -$412.8 million (cross-validated within 0.00% deviation) | Wikipedia 10-K data and Barchart | July 13, 2026 |
This AGIO AI stock analysis page is an informational tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available data as of July 13, 2026, may be incomplete, and can be wrong if new filings, FDA decisions, clinical data, competitive events, market prices, or macro conditions change. Biotech investments carry binary event risk.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
